A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma (SUNRISE)
18 Years - 80 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Sept 2023 by AstraZeneca
No locations available
Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.
Tezepelumab subcutaneous injection
Other Name: Tezepelumab
|Placebo Comparator: Placebo|
Placebo subcutaneous injection, in an accessorised pre-filled syringe.
Placebo subcutaneous injection
Other Name: Placebo